The model project VERhO – Optimizing Care of Patients Suffering from Rheumatoid Arthritis has been funded since 2016 as part of the Innovation Fund of the Gemeinsamer Bundesausschuss.
More and more patients suffering from rheumatoid arthritis benefit from modern, anti-inflammatory drugs. Once the symptoms of the disease have subsided, these drugs can be reduced in some patients and in some cases even discontinued altogether. Together with the consortium partners Berufsverband Deutscher Rheumatologen e.V., University of Hamburg, Techniker Krankenkasse and mhplus Betriebskrankenkasse, we want to systematically implement and evaluate a gradual reduction of anti-rheumatic drugs in conjunction with close disease monitoring in a large number of patients with rheumatoid arthritis in the VERhO model project. Based on the data obtained from VERhO, a comprehensive treatment program for rheumatoid arthritis will be established to provide patients with targeted and tailored therapy, avoiding both under- and over-treatment. In addition, the patient data will be processed for a central registry that can be used to answer further questions.
Scientific Management: Prof. Dr. med. Georg Schett